Richmond Pharmacology is delighted with the acknowledgement and features at 96 in the list of 200.

The report is the first of its kind and refers to the high-growth companies founded or led by women or have management teams that are at least 50% women.

Richmond Pharmacology qualifies for the list as it was co-founded by Medical Director Dr Ulrike Lorch and has equal representation in senior management roles throughout the business.

J.P. Morgan Private Bank's list of the top 200 female-powered businesses showcases private UK businesses that have grown sales, headcount or valuation at exceptional rates. To be eligible, companies must have grown at least one of these metrics and observed this growth in the 12 months prior to 31 October 2020. In total, it analyses the 6,085 high growth companies in the UK which meet the criteria.

Dr Ulrike Lorch commenting on the success, said, "We are delighted that Richmond Pharmacology has been recognised as one of the top high-growth companies where women form a significant proportion of the founder and leadership teams. It has been a rewarding journey from founding the company to where we are now: an innovative and highly specialised team of people who play an essential part in the development of new medicines. Men and women have always had equal roles at Richmond Pharmacology - from entry positions to the boardroom - and we share our success as a collective."

Richmond Pharmacology is proud of our diverse and inclusive culture. Currently, women contribute to over half of the collective workforce. Learn more about the JP Morgan Top 200 Female Powered Businesses. Download the report here.

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event